

Development and application of an early warning model for predicting early mortality following stent placement in malignant biliary obstruction: A comparative analysis of logistic regression and artificial neural network approaches

YONGXIN MA^{1,2}, JIAOJIAO QI³, XUSHENG ZHANG^{1,2}, KEJUN LIU^{1,2}, YIMIN LIU²,
XUEHAI YU⁴, YANG BU^{1,2} and BENDONG CHEN^{1,2}

¹Department of Hepatobiliary Surgery, General Hospital of Ningxia Medical University, Yinchuan, Ningxia 750004, P.R. China; ²Department of Hepatobiliary Surgery, First Clinical College of Medicine, Ningxia Medical University, Yinchuan, Ningxia 750004, P.R. China; ³Department of Obstetrics Function Center Inspection, General Hospital of Ningxia Medical University, Yinchuan, Ningxia 750004, P.R. China; ⁴Department of Pediatric Surgery, General Hospital of Ningxia Medical University, Yinchuan, Ningxia 750004, P.R. China

Received October 15, 2024; Accepted February 28, 2025

DOI: 10.3892/ol.2025.14983

Abstract. Patients with malignant biliary obstruction (MBO) are often treated with endoscopic retrograde cholangiopancreatography (ERCP) combined with biliary stent placement for tumor progression. However, certain patients die within 30 days after the procedure, increasing healthcare resource consumption and patient burden. Therefore, the development of early mortality prediction models is important for optimizing treatment decisions. The present study retrospectively analyzed the clinical data of 285 patients with MBO, including demographic information, laboratory indicators and tumor-related factors. Logistic regression and artificial neural network (ANN) models were used to construct a prediction tool, and the model performance was evaluated using area under the curve (AUC), accuracy, sensitivity and specificity. The logistic regression model, which identified the cancer antigen 19-9 (CA19-9) level and a history of previous ERCP surgery as independent risk factors, had an AUC of 0.727 and an accuracy of 65.0%. The ANN model, which combined five variables, namely CA19-9, history of previous ERCP surgery, neutrophil-lymphocyte ratio (NLR), liver metastasis and carcinoembryonic antigen, demonstrated that NLR was the most weighted predictor. Furthermore, the ANN model had

an AUC of 0.813, an accuracy of 88.2% and a specificity that was markedly higher than that of the logistic regression model (95.5 vs. 83.3%). However, the ANN model was revealed to be slightly less sensitive compared with the logistic regression model (61.1 vs. 61.2%). In conclusion, compared with logistic regression, the ANN model had a greater performance level in terms of predictive power and specificity, and is suitable for capturing complex non-linear relationships. However, its complexity and risk of overfitting need to be further optimized. The present study provides a new tool for the accurate prediction of the risk of early death after ERCP in patients with MBO, which could help improve individualized treatment strategies.

Introduction

Malignant biliary obstruction (MBO) is a spectrum of disorders in which malignant tumors cause narrowing of the bile ducts, thereby affecting bile excretion. Common causes include cholangiocarcinoma, gallbladder cancer, pancreatic cancer, bladder cancer and metastatic tumors. However, this disease usually progresses insidiously, resulting in >80% of patients being ineligible for radical surgery at the time of diagnosis (1,2). Therefore, endoscopic retrograde cholangiopancreatography (ERCP) combined with biliary stenting has become the treatment of choice for patients with MBO who cannot undergo radical surgery. This approach is favored for its minimally invasive nature, high success rate and good patient tolerability (3,4). However, a study in the United Kingdom reported an early mortality rate of 19.1% within 30 days after ERCP, with a higher rate of 25.3% in patients with severe biliary obstruction (5,6). In patients with early mortality within 30 days postoperatively, the main purpose of ERCP stent implantation is to ensure biliary patency and drainage. In such cases, the placement of plastic stents is sufficient to guarantee the continuation of the life of the patient, and the advantages of metal stents in terms of duration of use

Correspondence to: Professor Yang Bu or Professor Bendong Chen, Department of Hepatobiliary Surgery, General Hospital of Ningxia Medical University, 804 Shengli South Street, Xingqing, Yinchuan, Ningxia 750004, P.R. China
E-mail: boyang1976@163.com
E-mail: chenbendong@nxmu.edu.cn

Key words: malignant biliary obstruction, endoscopic retrograde cholangiopancreatography, early mortality, artificial neural networks, logistic regression models

and patency are null and void, whereas their high cost imposes a significant financial burden on the patient and the healthcare system (7). Therefore, it is urgent to predict the risk of early postoperative mortality and to select clinical protocols based on the expected survival time of patients with MBO.

Currently, most studies on early death within 30 days after ERCP in patients with MBO have focused on the analysis of risk factors associated with postoperative death (6,8), whilst modeling studies aimed at predicting early death within 30 days after ERCP in patients with MBO are scarce. This makes it difficult to effectively predict the risk of early postoperative death with preoperative data and to screen high-risk patients with preoperative information. Kalaitzakis (9) predicted the risk of early death within 30 days after ERCP in patients with biliary obstruction by analyzing demographic characteristics, mode of admission and comorbidities; however, the study included patients with benign biliary obstruction. Zhu *et al* (10) reported that factors such as distant metastasis, total bilirubin level, post-ERCP complications and successful drainage were associated with early death within 30 days after ERCP in patients with MBO; however, the exploration of the general condition of the patients and tumor-related factors was not comprehensive. Furthermore, most of these studies were limited to a small number of laboratory indicators, and their predictive ability still needs to be further validated and evaluated. To achieve accurate early warning of early death within 30 days after surgery, new early warning models need to be constructed and validated based on more comprehensive preoperative data, including laboratory indicators, tumor-related factors and the general health status of patients.

It is currently common practice to use traditional statistical methods, such as logistic regression, to build simple and easy-to-use predictive models. However, as patients with MBO may have multiple tumor types, which results in increased complexity of features and possible correlations among features, traditional statistical methods may not be able to effectively address this complexity (11,12). By contrast, an artificial neural network (ANN), as an advanced machine learning technique, can learn the relationship between complex features and outcomes from a large amount of heterogeneous data (13), which provides new ideas and strong support for the establishment of clinical prediction models.

Therefore, the present study aimed to assess the potential clinical predictors of death within 30 days after ERCP in patients with MBO using comprehensive clinical data and construct a visualized prediction model. Furthermore, the present study aimed to build a simple ANN model to evaluate its predictive ability and compare it with the traditional model to verify the advantages and disadvantages of the performance of both in clinical applications.

Materials and methods

Patient selection. A total of 625 patients, diagnosed with MBO through imaging and/or pathology and treated with ERCP combined with biliary stenting at the Department of Hepatobiliary Surgery in the General Hospital of Ningxia Medical University (Yinchuan, China) between January 2018 and September 2021, were included in the present study. After excluding 340 patients, a total of 285 patients were included.

The specific study procedure and patient selection are outlined in Fig. 1. Prior to surgery, all patients provided written informed consent for the procedure. The study was approved by the Ethics Committee of the General Hospital of Ningxia Medical University (approval no. KYLL-2023-0450). The inclusion criteria were as follows: i) Age of >18 years; ii) sufficient evidence (imaging and pathology) to diagnose MBO; and iii) inability to perform surgical resection of the lesion due to lesion progression, metastasis and poor general condition. The exclusion criteria were as follows: i) Serious infection or organ failure before surgery; ii) Eastern Cooperative Oncology Group (ECOG) score of 4 (14); iii) received other antitumor treatment within 1 month after surgery, such as percutaneous transhepatic cholangial drainage or endoscopic ultrasound-guided biliary stenting (except symptomatic supportive treatment); iv) incomplete clinical data; v) other surgery within 30 days after surgery; and vi) other accidental death due to non-disease causes (such as from traffic accidents or suicide).

Data collection. The data collected included several clinical characteristics of the patients. Demographic information, such as age, sex and body mass index, was recorded. General information, such as liver function Child-Pugh classification (15), ECOG score, history of previous ERCP, history of abdominal surgery and history of gallstones, was also documented. Laboratory markers, including white blood cell count, hemoglobin, total bilirubin, direct bilirubin, albumin and glucose levels, neutrophil-lymphocyte ratio count (NLR), cancer antigen 19-9 (CA19-9), carcinoembryonic antigen (CEA), alanine aminotransferase, aspartate aminotransferase, lactate dehydrogenase and alkaline phosphatase levels, and prothrombin time, were measured and recorded. Other indicators, such as the length and location of the obstruction, presence of biliary infection, presence of liver metastasis, presence of abdominal lymph node metastasis, presence of distant metastasis and type of stent used, were also documented. Surgical time was categorized as <30 and ≥30 min based on previous studies (16,17). In the present study, due to the limitation of the number of cases, obstruction was categorized according to the location of the obstruction, with high biliary obstruction considered as above the site of the confluence of the cystic duct and common bile duct, and low biliary obstruction considered as below it (18). Obstruction length was determined using intraoperative ERCP angiography.

The data collection process was performed retrospectively, ensuring that all relevant clinical information was recorded accurately and comprehensively. This comprehensive dataset allowed for a thorough analysis of the potential risk factors associated with early death after ERCP in patients with MBO.

ERCP method of operation. A thorough preoperative laboratory and examination was performed to rule out contraindications to ERCP. CT and MRI were performed to assess the location of the tumor, the degree of invasion and the type of bile duct stricture. The intraoperative decision to perform a sphincterotomy of Oddi was based on the difficulty of intubation. Stents were selected based on observations of the location and extent of the stricture, and the internal diameter of the bile duct. In certain patients with high MBO obstruction, pathological sampling and stenting were performed under direct vision using the Spyglass transoral




Figure 1. Flowchart of the model test for predicting the occurrence of early death within 30 days after ERCP combined with biliary stenting. ERCP, endoscopic retrograde cholangiopancreatography; MBO, malignant biliary obstruction; ANN, artificial neural network.

choledochoscope fiberoptic direct vision system (Olympus, Corp.). Postoperatively, the patients were treated with primary care, acid and enzyme suppression, prophylactic anti-infectives and other symptomatic supportive therapy.

Study endpoints and related definitions. According to the relevant literature, early deaths are defined as those occurring within 30 days following ERCP (6,19). Therefore, the endpoint event of the present study was to determine whether early death occurred in patients with MBO after undergoing ERCP combined with biliary stent placement. Patient death

was primarily due to disease progression or disease-related events, excluding accidental deaths unrelated to the underlying condition (such as traffic accidents or suicides).

Statistical analysis. Statistical analyses were performed using SPSS 26.0 software (IBM Corp.) and the R language package (4.1.3; R Package for Statistical Computing; www.r-project.org). Data are presented as median (interquartile range) or n (%). The unpaired Student's t-test or the Mann-Whitney U test were used for continuous variables, and Pearson's χ^2 test or Fisher's exact test were used for categorical data. Univariate analysis was used

Table I. Characteristics of the patients in the training and validation groups.

Variable	Training group (n=200)	Validation group (n=85)	χ^2/Z	P-value
Sex				
Male	108 (54.0)	47 (55.3)	0.04	0.841
Female	92 (46.0)	38 (44.7)		
Age, years	72.0 (64.0-78.0)	73.0 (67.5-79.0)	-0.946	0.344
BMI, kg/m ²	22.0 (20.3-24.6)	22.2 (21.5-23.3)	-0.446	0.655
Infections				
Yes	51 (25.5)	28 (32.9)	1.648	0.199
No	149 (74.5)	57 (67.1)		
Death				
Yes	39 (19.5)	18 (21.2)	0.105	0.746
No	161 (80.5)	67 (78.8)		
Ascites				
Yes	24 (12.0)	6 (7.1)	1.546	0.214
No	176 (88.0)	79 (92.9)		
History of ERCP				
Yes	61 (30.5)	27 (31.8)	0.045	0.833
No	139 (69.5)	58 (68.2)		
History of abdominal surgery				
Yes	49 (24.5)	14 (16.5)	2.233	0.135
No	151 (75.5)	71 (83.5)		
Liver metastasis				
Yes	34 (17.0)	8 (9.4)	2.734	0.098
No	166 (83.0)	77 (90.6)		
Lymph node metastases				
Yes	34 (17.0)	10 (11.8)	1.252	0.263
No	166 (83.0)	75 (88.2)		
Distant metastasis				
Yes	12 (6.0)	3 (3.5)	0.329	0.567
No	188 (94.0)	82 (96.5)		
ECOG score				
0	7 (3.5)	4 (4.7)	-0.132	0.895
1	45 (22.5)	18 (21.2)		
2	104 (52.0)	43 (50.6)		
3	44 (22.0)	20 (23.5)		
Child-Pugh class				
A	15 (7.5)	13 (15.3)	-1.166	0.224
B	172 (86.0)	65 (76.5)		
C	13 (6.5)	7 (8.2)		
Type of malignancy				
Gallbladder cancer	8 (4.0)	4 (4.7)	0.547	0.990
Cholangiocarcinoma	67 (33.5)	28 (32.9)		
Pancreatic cancer	41 (20.5)	17 (20.0)		
Liver cancer	21 (10.5)	7 (8.2)		
Ampullary cancer	27 (13.5)	12 (14.1)		
Metastatic cancer	36 (18.0)	17 (20.0)		
Obstruction site				
High obstruction	78 (39.0)	38 (44.7)	0.805	0.370
Low obstruction	122 (61.0)	47 (55.3)		
Obstruction length, mm	21.0 (11.2-31.8)	20.0 (13.0-31.0)	-0.385	0.700
Stent type				
Plastic stent	32 (16.0)	13 (15.3)	1.587	0.662

Table I. Continued.

Variable	Training group (n=200)	Validation group (n=85)	χ^2/Z	P-value
Metal stent	36 (18.0)	17 (20.0)		
Metal + nasobiliary drainage	48 (24.0)	15 (17.6)		
Nasal biliary drainage	84 (42.0)	40 (47.1)		
CA19-9				
≥240 U/ml	103 (51.5)	41 (48.2)	0.254	0.614
<240 U/ml	97 (48.5)	44 (51.8)		
CEA				
≥5 ng/ml	76 (38.0)	25 (29.4)	1.923	0.166
<5 ng/ml	124 (62.0)	60 (70.6)		
WBC, $\times 10^9/l$	6.4 (5.0-7.7)	6.5 (5.5-8.1)	-1.379	0.168
NLR	3.9 (2.6-5.8)	4.4 (2.4-6.1)	-0.790	0.429
HGB, g/l	125.0 (111.0-135.0)	124.0 (108.5-134.5)	-0.526	0.599
TBIL, $\mu\text{mol/l}$	198.3 (93.2-296.3)	189.0 (67.5-307.0)	-0.595	0.552
DBIL, $\mu\text{mol/l}$	102.5 (27.8-181.6)	103.0 (14.0-187.5)	-0.137	0.891
ALB, g/l	33.4 (30.0-37.1)	32.6 (29.3-36.9)	-0.888	0.374
ALT, U/l	124.8 (69.8-192.3)	125.0 (68.9-204)	-0.016	0.987
AST, U/l	112.0 (58.6-205.1)	109.0 (60.8-200.5)	-0.150	0.881
LDH, U/l	485.0 (375.0-648.0)	471.0 (367.0-617.0)	-0.778	0.436
ALP, U/l	341.3 (230.2-541.0)	314.0 (205.5-624.5)	-0.095	0.924
PT, sec	12.3 (11.3-13.2)	12.6 (11.4-13.7)	-1.582	0.114

Measurement data are expressed as median (interquartile range) and count data are expressed as n (%). BMI, body mass index; ERCP, endoscopic retrograde cholangiopancreatography; ECOG, Eastern Cooperative Oncology Group; CA19-9, cancer antigen 19-9; CEA, carcino-embryonic antigen; WBC, white blood cell count; NLR, neutrophil-lymphocyte ratio count; HGB, hemoglobin; TBIL, total bilirubin; DBIL, direct bilirubin; ALB, albumin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; LDH, lactate dehydrogenase; ALP, alkaline phosphatase; PT, prothrombin time.

in the training group to screen for potential risk factors associated with 30-day mortality, $P < 0.05$ was considered to indicate a statistically significant difference.

Potential risk factors identified in a multifactorial analysis were included in the logistic regression model, which was constructed using independent risk factors, with $P < 0.05$. The odds ratio (OR) and 95% confidence interval (CI) for the predictors were calculated, and the model was visualized using a column-line graph based on the logistic results. Furthermore, the 'Neural Network' module in SPSS 26.0 software was used to construct the 'Multilayer Perceptron' ANN model. The model had three layers: Input layer, hidden layer and output layer. The covariates were rescaled using a standardized method. The activation function of the hidden layer was the hyperbolic tangent function; the training type was batch training; the optimization algorithm chose conjugate gradient; the initial sigma was set to 0.00005; the interval offset was ± 0.5 ; the maximum training time was set to 15 min; the minimum relative change of training error was 0.0001; the minimum relative change of the training error rate was 0.001; and the output layer used the softmax function and the error function used cross-entropy. As training progressed, the neural network model gradually increased the accuracy of its correlation weight coefficients, and when the training was complete, the ANN was constructed.

In the present study, the predictive ability of the logistic and ANN models was comprehensively assessed, validated and compared through different indicators, including area under the curve (AUC) with 95% confidence interval (CI), accuracy, sensitivity and specificity. AUC is a key indicator for assessing the discriminative ability of a model; it can be used to reflect the overall discriminative ability of a model for positive and negative samples by plotting receiver operator characteristic (ROC) curves. Moreover, the 95% CIs of AUC values demonstrate the statistical reliability of the results and can assess the stability and significance of the model performance. Accuracy is an important indicator for assessing the correct classification of the model, which can evaluate the overall performance of the dataset. Sensitivity measures the ability of the model to detect positive cases, which can be used to assess the model's ability to recognize positive cases and helps assess the model's false-negative rate, and specificity reflects the ability of the model to correctly identify the negative cases, which helps to assess the misdiagnosis rate of the model. These metrics comprehensively evaluate the performance of the model from multiple dimensions, such as overall performance, positive case detection ability and negative case exclusion ability, respectively. Therefore, these indicators of AUC with 95% CI, accuracy, sensitivity and specificity can be used to compare the predictive performance of logistic regression models and ANN models, and to clarify their respective advantages and

Table II. Univariate analysis of 30-day mortality-related risk factors.

Variable	Died within 30 days (n=39)	No death within 30 days (n=161)	χ^2/Z	P-value
Sex				
Male	22 (56.4)	86 (53.4)	0.113	0.736
Female	17 (43.6)	75 (46.6)		
Age, years	75.0 (67.0-78.0)	72.0 (64.0-78.0)	-1.273	0.203
BMI, kg/m ²	21.9 (19.6-24.5)	22.4 (20.6-24.7)	-0.785	0.433
Infections				
Yes	11 (28.2)	40 (24.8)	0.187	0.666
No	28 (71.8)	121 (75.2)		
Ascites				
Yes	4 (10.3)	20 (12.4)	0.139	0.709
No	35 (89.7)	141 (87.6)		
History of ERCP				
Yes	19 (48.7)	42 (26.1)	7.585	0.006
No	20 (51.3)	119 (73.9)		
History of abdominal surgery				
Yes	9 (23.1)	40 (24.8)	0.053	0.818
No	30 (76.9)	121 (75.2)		
Liver metastasis				
Yes	11 (28.2)	23 (14.3)	4.311	0.038
No	28 (71.8)	138 (85.7)		
Lymph node metastases				
Yes	9 (23.1)	25 (15.5)	1.268	0.260
No	30 (76.9)	136 (84.5)		
Distant metastasis				
Yes	4 (10.3)	8 (5.0)	0.742	0.389
No	35 (89.7)	153 (95.0)		
ECOG score				
0	1 (2.6)	6 (3.7)	-0.923	0.356
1	7 (17.9)	38 (23.6)		
2	21 (53.8)	83 (51.6)		
3	10 (25.6)	34 (21.1)		
Child-Pugh class				
A	1 (2.6)	14 (8.7)	-0.668	0.504
B	36 (92.3)	136 (84.5)		
C	2 (5.1)	11 (6.8)		
Type of malignancy				
Gallbladder cancer	0 (0.0)	8 (5.0)	7.218	0.205
Cholangiocarcinoma	10 (25.6)	57 (35.4)		
Pancreatic cancer	12 (30.8)	29 (18.0)		
Liver cancer	5 (12.8)	16 (9.9)		
Ampullary cancer	6 (15.4)	21 (13.0)		
Metastatic cancer	6 (15.4)	30 (18.6)		
Obstruction site				
High obstruction	15 (38.5)	63 (39.1)	0.006	0.939
Low obstruction	24 (61.5)	98 (60.9)		
Obstruction length, mm	23.0 (15.0-35.0)	21.0 (11.0-31.5)	-1.014	0.311
Stent type				
Plastic stent	6 (15.4)	31 (19.3)	5.736	0.125
Metal stent	8 (20.5)	28 (14.7)		

Table II. Continued.

Variable	Died within 30 days (n=39)	No death within 30 days (n=161)	χ^2/Z	P-value
Metal stent and nasobiliary drainage	14 (35.9)	32 (19.9)		
Nasal biliary drainage	11 (28.2)	70 (43.5)		
CA19-9				
≥240 U/ml	30 (76.9)	73 (45.3)	12.536	<0.001
<240 U/ml	9 (23.1)	88 (54.7)		
CEA				
≥5 ng/ml	21 (53.8)	55 (34.2)	5.163	0.023
<5 ng/ml	18 (46.2)	106 (65.8)		
WBC, x10 ⁹ /l	7.0 (5.3-8.5)	6.2 (5.0-7.6)	-1.912	0.056
NLR	5.9 (4.2-8.9)	3.5 (2.4-5.0)	-4.655	<0.001
HGB, g/l	124.0 (111.0-140.0)	125.0 (111.0-134.5)	-0.295	0.768
TBIL, μmol/l	203.0 (72.8-267.0)	194.5 (97.5-305.2)	-0.544	0.586
DBIL, μmol/l	121.0 (74.8-163.7)	86.9 (14.7-185.1)	-1.573	0.116
ALB, g/l	32.5(28.9-35)	33.6 (30.0-37.3)	-1.221	0.222
ALT, U/l	133.3(98.5-193.0)	114.0 (67.3-192.0)	-1.238	0.216
AST, U/l	120.2 (73.0-195.0)	111.0 (54.9-206.6)	-0.683	0.495
LDH, U/l	527.0 (346.0-690.0)	471.0 (375.0-644.0)	-0.791	0.429
ALP, U/l	401.3 (265.7-536.0)	328.0 (220.1-544.9)	-0.937	0.349
PT, sec	12.4 (11.6-13.1)	12.1 (11.3-13.3)	-0.578	0.563

Measurement data are expressed as median (interquartile range) and count data are expressed as n (%). BMI, body mass index; ERCP, endoscopic retrograde cholangiopancreatography; ECOG, Eastern Cooperative Oncology Group; CA19-9, cancer antigen 19-9; CEA, carcino-embryonic antigen; WBC, white blood cell count; NLR, neutrophil-lymphocyte ratio count; HGB, hemoglobin; TBIL, total bilirubin; DBIL, direct bilirubin; ALB, albumin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; LDH, lactate dehydrogenase; ALP, alkaline phosphatase; PT, prothrombin time.

disadvantages, to more comprehensively guide the selection in practical applications.

Results

Baseline characteristics. The 285 patients who were included in the present study were randomized into a training group (n=200) and a validation group (n=85). A total of 155 patients were male and 130 were female, with ages ranging from 35-90 years. The distribution of cancer types was as follows: Cholangiocarcinoma, n=95; gallbladder carcinoma, n=12; pancreatic carcinoma, n=58; hepatocellular carcinomas involving the first hepatic hilar, n=28; pancreatic carcinoma, n=39; and metastatic carcinoma, n=53. The incidence of early postoperative death was 20.0% (57/285). Of these cases, 39 occurred in the training group and 18 in the validation group. Analysis of the case records revealed that the causes of death were progressive malignant disease in 32 cases, cholangitis in 17 cases, acute liver failure in 5 cases, gastrointestinal hemorrhage in 1 case, cardiac arrest in 1 case and acute pulmonary edema in 1 case. No statistically significant differences were demonstrated between the modeling and validation groups for any of the assessed characteristics. The data for the characteristics of each group are presented in Table I.




Figure 2. Receiver operating characteristic, AUC and optimal cut-off values of CA19-9 for predicting 30-day mortality. According to the maximum Youden index, the optimal cut-off value of CA19-9 is 238.850 U/ml, which is equal to ~240 U/ml for simplified statistics (20). AUC, area under the curve; CI confidence interval; CA19-9, cancer antigen 19-9; FPR, false positive rate; TPR, true positive rate.

Table III. Multivariate logistic regression analysis.

Variable	β	SE	Wald	P-value	Exp(B)	95% CI
CA19-9	1.690	0.457	13.685	<0.001	5.417	2.213-13.259
History of ERCP	1.366	0.430	10.081	0.001	3.919	1.687-9.106
Liver metastasis	0.788	0.479	2.704	0.100	2.200	0.860-5.630
NLR	0.083	0.044	3.586	0.058	1.087	0.997-1.185
CEA	0.717	0.409	3.066	0.080	2.048	0.918-4.570
Constant	-3.899	0.560	48.189	<0.001	0.020	-

CA19-9, cancer antigen 19-9; ERCP, endoscopic retrograde cholangiopancreatography; NLR, neutrophil-lymphocyte ratio count; CEA, carcinoembryonic antigen; SE, standard error; CI, confidence interval.




Figure 3. Nomogram of logistic model predicting the risk of early death within 30 days after ERCP combined with biliary stenting. The upper scale is the score of each variable, and the total score of the two variables was obtained. The corresponding lower scale is the risk of early death within 30 days. ERCP, endoscopic retrograde cholangiopancreatography; CA19-9, cancer antigen 19-9.

Risk factor analysis for early death. The results of univariate analysis in the training group revealed five potential risk factors associated with the risk of 30-day post-ERCP mortality in patients with MBO. These factors included a history of previous ERCP surgery, CA19-9 levels, CEA levels, liver metastasis and NLR (Table II). CA19-9 levels ranged from 2 U/ml to 1,200 U/ml, and for the purpose of statistical analysis, the optimal cutoff value of 240 U/ml was determined based on the maximum Jordon index (20). This value was then categorized into high and low levels (Fig. 2) and transformed into a binary variable. Similarly, the range of values for CEA was also wide, and the upper limit of the normal value (4.7 ng/ml) was used as the cutoff value. To simplify the statistical analysis, a cutoff value of 5 ng/ml was used, transforming it into a dichotomous variable.

Logistic regression model. A total of two independent risk factors, ERCP history and CA 19-9 levels, were identified through multifactorial logistic regression analysis (Table III).

A logistic regression model was then constructed: $Y = \text{Logit } P = -3.899 + 1.690 \times \text{CA19-9} + 1.366 \times \text{ERCP history}$. To visualize the model, a nomogram was created (Fig. 3).

Logistic model calibration plots demonstrated no statistically significant difference between predicted and true values (Fig. 4). The Bootstrap method revealed a c-value of 0.727 for the training group and 0.761 for the validation group, and the Hosmer-Leme show test demonstrated a P-value of 0.934 for the training group and 0.915 for the validation group. Therefore, this indicated that the model had good prediction performance. Furthermore, the AUC values for each group determined using the ROC curves were 0.727 for the training group and 0.771 for the validation group (Fig. 5; Table IV).

ANN model. ANN models were constructed based on the five potential risk factors obtained from univariate analysis using samples from the training and validation groups. Among them, NLR was used as a covariate, and the remaining four variables were dichotomous, including CA19-9 level,




Figure 4. Calibration diagram of the logistic model predicting the risk of early death within 30 days after endoscopic retrograde cholangiopancreatography combined with biliary stenting. (A) Training group. (B) Verification group. The abscissa (x) represents the predicted value, the ordinate (y) represents the true value and the solid line ($y=x$) in the graph represents the ideal situation (the predicted value is the same as the true value).




Figure 5. Receiver operating characteristic curves of the logistic model predicting the risk of early death within 30 days after endoscopic retrograde combined with biliary stenting in the training and validation groups. (A) Training group. (B) Validation group. AUC, area under the curve; CI confidence interval; FPR, false positive rate; TPR, true positive rate.

CEA level, liver metastasis and history of ERCP surgery. The ANN model used in the present study was a multilayer perceptron ANN, including an input layer (five variables), an implicit layer and an output layer (dichotomous endings) (Fig. 6). Moreover, the ANN model had an AUC value of 0.813 (Fig. 7), and the degree of importance of the variables in the ANN model was expressed in terms of significance

and standardized significance in descending order (Table V; Fig. 8). The prediction efficiency of the ANN model is presented in Table VI.

Validation and comparison of models. The predictive performance of the logistic and ANN models was internally and externally validated in the training and validation groups, and

Table IV. Prediction efficiency of the logistic model training and validation groups.

Variable	Training group	Validation group
Sensitivity, %	54.7	61.2
Specificity, %	76.9	83.3
Accuracy, %	59.0	65.0
Area under the curve	0.727	0.771

Table V. Importance of independent variables and normalization in the artificial neural network model.

Variable	Importance	Standardized importance, %
CA19-9	0.216	54.6
History of ERCP	0.215	54.5
Liver metastasis	0.126	31.9
CEA	0.047	12.0
NLR	0.395	100.0

CA19-9, cancer antigen 19-9; ERCP, endoscopic retrograde cholangiopancreatography; NLR, neutrophil-lymphocyte ratio count; CEA, carcinoembryonic antigen.

Table VI. Prediction efficiency of the artificial neural network model in the training and validation groups.

A, Training group			
Actual measurement	Prediction		Correctness, %
	0	1	
0	151	10	93.8
1	19	20	51.3
Overall, %	85.0	15.0	85.5

B, Validation group			
Actual measurement	Prediction		Correctness, %
	0	1	
0	64	3	95.5
1	7	11	61.1
Overall, %	83.5	16.5	88.2

Outcome event was whether the patient died within 30 days: 1, outcome event occurred; 0, outcome event did not occur.

the predictive abilities were compared (Table VII). The accuracy of the logistic model was 59.0 and 65.0% in the training and validation groups, respectively, and the accuracy of the

Table VII. Comparison of the prediction performance between the logistic and ANN models.

A, Logistic model			
Group	Accuracy, %	Sensitivity, %	Specificity, %
Training	59.0	54.7	76.9
Validation	65.0	61.2	83.3

B, ANN model			
Group	Accuracy, %	Sensitivity, %	Specificity, %
Training	85.5	51.3	93.8
Validation	88.2	61.1	95.5

ANN, artificial neural network.

ANN model was 85.5 and 88.2% in the training and validation groups, respectively. The latter was markedly higher than that of the logistic model, indicating that the ANN model had a stronger overall predictive ability. The sensitivity of the logistic model in the training and validation groups was 54.7 and 61.2% in the training and validation groups respectively, and the sensitivity of the ANN model was 51.3% in the training group and 61.1% in the validation group; therefore, the difference between the models was not notably different in the same group. However, the sensitivity of the ANN model was still slightly weaker, suggesting that it may have certain deficiencies in the capture of positive samples. Furthermore, the specificity of the logistic model was 76.9 and 83.3% in the training and validation groups, respectively, while the specificity of the ANN model was as high as 93.8 and 95.5% in the training and validation groups, respectively. This indicates that the ANN model has an improved predictive ability and a marked advantage in identifying negative samples.

Discussion

MBO is a group of diseases in which the bile duct is blocked or compressed by a malignant tumor, resulting in biliary stricture or obstruction of bile drainage. Currently, ERCP is the palliative treatment of choice for patients with MBO (5). ERCP treatment involves placement of biliary stents, and plastic and metal stents are common options. Studies have reported that there is no significant difference in the use of metal and plastic stents in the effectiveness of biliary drainage and risk of adverse events in patients who die within 30 days of ERCP treatment (21,22); however, plastic stents are more cost-effective, providing effective treatment and saving healthcare resources whilst reducing the economic burden on patients and society (8,23). Accurate prediction of prognosis after ERCP is of great importance for clinical decision support and appropriate treatment selection. Currently, there are few existing reports on predicting this risk in patients with MBO. Therefore, the aim of the present study was to construct a model to predict the risk of death within 30 days after ERCP




Figure 6. Artificial neural network model for predicting the risk of early death occurring within 30 days after ERCP combined with biliary stenting. The first layer is the input layer, the second layer is the hidden layer, using the hyperbolic tangent function, and the third layer is the output layer, using the softmax function. The grey connection lines indicate a positive weight value, and the blue connection lines indicate a negative weight value. CA19-9, cancer antigen 19-9; ERCP, endoscopic retrograde cholangiopancreatography; LM, liver metastasis; CEA, carcinoembryonic antigen; NLR, neutrophil-to-lymphocyte ratio; H, hidden layer.

combined with biliary stent placement in patients with MBO. The model utilized preoperative clinical data and employed both logistic and ANN models. The predictive ability of these two models was evaluated and compared.

In the present study, all indicators associated with the risk factors, including history of previous ERCP surgery, CA19-9 levels, CEA levels, liver metastasis and NLR, were easily available before the surgery. The logistic model was presented succinctly and intuitively through column-line graphs, whereas the ANN model appeared to be complex and inconvenient to use. In both the training and validation groups, the accuracy of the ANN model (85.5 and 88.2%, respectively) was notably higher than that of the logistic model (59.0 and

65.0%, respectively), suggesting that the ANN model had a stronger overall predictive ability. This may be attributed to the more complex structure and non-linear fitting ability of the ANN model, allowing it to capture deeper features in the data. However, it is important to note that ANN models may overfit the training data, which potentially reduces the generalization ability when dealing with new data (24). Sensitivity is an important measure of the ability of a model to recognize positive samples. The sensitivity of the logistic model in the training and validation groups was 54.7 and 61.2%, respectively, whilst the sensitivity of the ANN model was 51.3 and 61.1%, respectively. Despite the slight increase in the sensitivity of the ANN model in the validation group compared




Figure 7. Receiver operating characteristic curves of the artificial neural network model for predicting the risk of early death within 30 days after ERCP combined with biliary stenting. ERCP, endoscopic retrograde cholangiopancreatography; AUC, area under the curve.




Figure 8. Importance of variables in the artificial neural network model for predicting the risk of early death within 30 days after ERCP combined with biliary stenting. ERCP, endoscopic retrograde cholangiopancreatography; NLR, neutrophil-to-lymphocyte ratio; CA19-9, cancer antigen 19-9; LM, liver metastasis; CEA, carcinoembryonic antigen.

with the training group, the overall sensitivity of both models was low, especially the sensitivity of the ANN model, which was markedly lower than its specificity. This may indicate certain limitations in the performance of the ANN model in the case of an insufficient number of positive samples or a sample imbalance. This also suggests the necessity of further studies to be performed with large samples. The specificity of the ANN model reached 93.8 and 95.5% in the training and validation groups, respectively, which was notably higher than that of the logistic model (76.9 and 83.3%, respectively). This indicated that the high specificity of the ANN model provided a significant advantage in reducing misdiagnosis rates, making it more suitable compared with the logistic model for identifying patients who die within 30 days after ERCP. The AUC value of the ANN model was 0.813, which was higher than that of the logistic model (AUC, 0.727), indicating that the ANN model had an improved performance in distinguishing between positive and negative samples. The difference in the AUC values further supports the superiority of the ANN model in terms of its overall performance, especially when dealing with complex data structures.

In addition, the ability of the ANN model to assign weights to predictor variables could aid in the identification of variables among the numerous risk factors that have the greatest impact on outcome. This is important for predicting early death within 30 days after ERCP. Conversely, the logistic model could only account for the impact of changes within variables on outcome (25,26). For example, in the present study, the ANN model identified NLR as the most important factor in predicting the risk of death after ERCP in patients with MBO (with an importance of 0.395 and a standardized importance of 100.0%), but the logistic model could only account for the effect of risk factors on outcomes by considering the results of the model and the OR values for each indicator.

In summary, the ANN model in the present study generally outperformed the logistic model in terms of prediction performance. The ANN model had strong non-linear approximation ability and was suitable for solving non-linear problems (27); it could self-learn and adjust according to the degree of error deviation to select the best model. By contrast, the logistic model was more suitable for datasets with relatively simple features and strong linear correlation. Nevertheless, there are certain disadvantages of using ANN models. First, there is a risk of overfitting the model, which may lead to overconfident predictions (28). Secondly, ANN models tend to be more complex in clinical applications compared with logistic models, which are more convenient. However, Pergialiotis *et al* (29) reported that these issues can be addressed by large sample studies. Small datasets may not be applicable to large cohorts, but the reverse is also possible.

Based on multifactorial regression analysis, the logistic model incorporated two independent risk factors: CA19-9 and a history of ERCP surgery. ERCP combined with biliary stenting does not prevent tumor progression (30,31), and ERCP surgery disrupts the biliary mucosal defense system as well as the physiological barrier between the bile ducts and intestines, which makes it easier for bacteria to invade the biliary system and cause prolonged inflammatory irritation of the bile ducts. These factors may accelerate the progression and metastasis of malignant tumors and severely affect the prognosis (32-34).

CA19-9 has been recognized as an important prognostic factor in several tumors, including gallbladder, bile duct, pancreatic and bladder cancer (35-37). The present study demonstrated that a CA19-9 level of ≥ 240 U/ml was an independent predictor of death within 30 days after ERCP in patients with MBO [OR (95% CI), 5.417 (2.213-13.259); $P < 0.001$]. Other potential risk factors have also been reported as prognostic predictors for biliopancreas-related malignancies, including NLR, CEA and liver metastases (23,38,39). These potential risk factors were not selected into the logistic model after multifactorial regression analysis but were important predictive variables in the ANN model. ANN models can obtain enough information from a set of variables to construct a predictive model, as ANN algorithms can derive complex and abstract non-linear relationships from the variables (40). The NLR is regarded as an amplifier of the systemic inflammatory response (41,42). Neutrophils influence the activation and recruitment of inflammatory cells through cytokines and chemokines, which in turn affects the proliferation and metastasis of tumor cells (43,44). By contrast, lymphocytes monitor the tumor immune microenvironment and inhibit the maturation of tumor cells, and a decrease in the total number of lymphocytes in the blood often predicts a poor prognosis (41,45). Moreover, elevated CEA levels are a prognostic factor for poor survival in certain patients with advanced malignancies (46,47). The incidence of liver metastases also increases with decreasing pathological differentiation, especially in cases of malignant biliary obstruction, and it has been reported that the survival time of patients with liver metastasis in MBO is significantly shortened compared with those without liver metastasis (48,49).

There are several limitations of the present study. First, the data were all retrospective, which is less persuasive than prospective data. Second, the samples used were all from a single center, were limited in number and were not validated with data external to the model, which may limit the generalizability of the model. Therefore, caution must be exercised in applying the findings to a wider population. Third, there may be a certain degree of subjectivity in the assessment of certain predictor variables, such as abdominal pain and ECOG score. Fourth, the ANN model constructed in the present study is the simplest one and needs further optimization. Due to the 'black box' nature of the ANN model, its internal processes involve complex neuronal computations and parameter adjustments, making it difficult to describe the input-output mapping using simple rules. This can pose challenges in the practical interpretation and application of the model; therefore, future studies should construct a simple and easy-to-use software or tool to facilitate the use of the ANN model. To overcome these limitations, prospective, multicenter and large-sample studies would be beneficial. Such a study design could provide more robust and reliable results that would optimize the model and more accurately predict the risk of death within 30 days after ERCP in patients with MBO.

In conclusion, the present study constructed and compared the performance of logistic and ANN models in predicting the risk of death within 30 days after ERCP combined with biliary stent placement in patients with MBO. The ANN model outperformed the logistic model in terms of overall predictive ability, accuracy and specificity. The ANN model was able to efficiently capture the complex non-linear relationships in the data, highlight important predictors such as NLR, and provide more accurate early warning information for clinical

decision-making. In the future, multi-center and large-sample prospective validation should be performed and simple and easy-to-use ANN model tools should be developed to further improve the generalization ability and operability of the model, which will be helpful for its wide application in clinical practice. Temporary alternative efficient and economical methods of biliary decompression should be recommended for high-risk patients who die within 30 days.

Acknowledgements

Not applicable.

Funding

The present study was supported by the 'Optimization of degradation-controllable magnesium alloy microparticles and their synergistic TACE against hepatocellular carcinoma and its mechanism' project (grant no. 2023SF13).

Availability of data and materials

The data generated in the present study may be requested from the corresponding author.

Authors' contributions

YM, JQ, XZ, KL, YL, XY, YB and BC contributed to the conception and design of the study. Material preparation, data collection and analysis were performed by YM, JQ and XZ. The first draft of the manuscript was written by YM. XY, KL and YL proposed amendments to the paper. YB and BC designed the study, provided guidance on manuscript writing, and contributed to its revision. YM and BC confirm the authenticity of all the raw data. All authors read and approved the final manuscript.

Ethics approval and consent to participate

The present study was approved by the Ethics Committee of the General Hospital of Ningxia Medical University (approval no. KYLL-2023-0450).

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Termsinsuk P, Charatcharoenwitthaya P and Pausawasdi N: Development and validation of a 90-day mortality prediction model following endobiliary drainage in patients with unresectable malignant biliary obstruction. *Front Oncol* 12: 922386, 2022.
2. Farani M, Saldi SRF, Maulahela H, Abdullah M, Syam AF and Makmum D: Survival, stent patency, and cost-effectiveness of plastic biliary stent versus metal biliary stent for palliation in malignant biliary obstruction in a developing country tertiary hospital. *JGH Open* 5: 959-965, 2021.
3. Dar FS, Abbas Z, Ahmed I, Atique M, Auja UI, Azeemuddin M, Aziz Z, Bhatti ABH, Bangash TA, Butt AS, *et al.*: National guidelines for the diagnosis and treatment of hilar cholangiocarcinoma. *World J Gastroenterol* 30: 1018-1042, 2024.
4. Drapek LC, Kerlan RK Jr and Acquistio S: Guidelines for biliary stents and drains. *Chin Clin Oncol* 9: 9, 2020.
5. Harvey PR, Baldwin S, Mytton J, Dosanjh A, Evison F, Patel P and Trudgill NJ: Higher volume providers are associated with improved outcomes following ERCP for the palliation of malignant biliary obstruction. *EClinicalMedicine* 18: 100212, 2020.
6. On W, Saleem MA, Hegade VS, Huggett MT, Paranandi B and Everett SM: Factors predicting 30-day mortality after ERCP in patients with inoperable malignant hilar biliary obstruction: A single tertiary referral centre experience and systematic review. *BMJ Open Gastroenterol* 9: e000878, 2022.
7. Lam R and Muniraj T: Fully covered metal biliary stents: A review of the literature. *World J Gastroenterol* 27: 6357-6373, 2021.
8. Lee TH, Moon JH and Park SH: Biliary stenting for hilar malignant biliary obstruction. *Dig Endosc* 32: 275-286, 2020.
9. Kalaitzakis E: All-cause mortality after ERCP. *Endoscopy* 48: 987-994, 2016.
10. Zhu Z, Hu K, Zhao F, Liu W, Zhou H, Zhu Z and Li H: Machine learning-based nomogram for 30-day mortality prediction for patients with unresectable malignant biliary obstruction after ERCP with metal stent: A retrospective observational cohort study. *BMC Surg* 23: 260, 2023.
11. Luo Y, Tan H, Yu T, Tian J and Shi H: A novel artificial neural network prognostic model based on a cancer-associated fibroblast activation score system in hepatocellular carcinoma. *Front Immunol* 13: 927041, 2022.
12. Rajula HSR, Verlatto G, Manchia M, Antonucci N and Fanos V: Comparison of conventional statistical methods with machine learning in medicine: Diagnosis, drug development, and treatment. *Medicina (Kaunas)* 56: 455, 2020.
13. Ataei A, Deng J and Muhammad W: Liver cancer risk quantification through an artificial neural network based on personal health data. *Acta Oncol* 62: 495-502, 2023.
14. Kitano R, Inoue T, Ibusuki M, Kobayashi Y, Ohashi T, Sumida Y, Nakade Y, Ito K and Yoneda M: Safety and efficacy of endoscopic retrograde cholangiopancreatography in patients with performance status 4. *Dig Dis Sci* 66: 1291-1296, 2021.
15. Kumada T, Toyoda H, Tada T, Yasuda S and Tanaka J: Changes in background liver function in patients with hepatocellular carcinoma over 30 years: Comparison of child-pugh classification and albumin bilirubin grade. *Liver Cancer* 9: 518-528, 2020.
16. Chan E, Neeman T and Thomson A: Follow-up to determine unplanned hospitalization and complications after endoscopic retrograde cholangiopancreatography. *ANZ J Surg* 88: E142-E146, 2018.
17. Teoh AYB, Napoleon B, Kunda R, Arcidiacono PG, Kongkam P, Larghi A, Van der Merwe S, Jacques J, Legros R, Thawee RE, *et al.*: EUS-Guided Choledochoduodenostomy using lumen apposing stent versus ERCP with covered metallic stents in patients with unresectable malignant distal biliary obstruction: A multicenter randomized controlled trial (DRA-MBO Trial). *Gastroenterology* 165: 473-482 e472, 2023.
18. Fu Z, Song J, Pi Y, Sun X, Liu M, Xiao Z and Chen J: A risk prediction model for post-endoscopic retrograde cholangiopancreatography pancreatitis after stent insertion for malignant biliary obstruction: Development and validation. *Dig Dis Sci* 68: 1574-1584, 2023.
19. Krill TS, Crain R, Al-Saadi Y, Stubbs S, Roark R, Chatila A, Haddad C, Kaushik C, Marcondes F, Guturu P and Parupudi S: Predictors of 30-day readmission after inpatient endoscopic retrograde cholangiopancreatography: A single-center experience. *Dig Dis Sci* 65: 1481-1488, 2020.
20. Zhou HF, Lu J, Zhu HD, Guo JH, Huang M, Ji JS, Lv WF, Li YL, Xu H, Chen L, *et al.*: Early warning models to estimate the 30-day mortality risk after stent placement for patients with malignant biliary obstruction. *Cardiovasc Intervent Radiol* 42: 1751-1759, 2019.
21. Kanno Y, Koshita S, Ogawa T, Kusunose H, Masu K, Sakai T, Yonamine K, Miyamoto K, Murabayashi T, Kozakai F, *et al.*: Inside plastic stents versus metal stents for treating unresectable malignant perihilar biliary obstructions: A retrospective comparative study. *Clin Endosc* 53: 735-742, 2020.
22. Park CH, Park SW, Jung JH, Jung ES, Kim JH and Park DH: Comparative efficacy of various stents for palliation in patients with malignant extrahepatic biliary obstruction: A systematic review and network meta-analysis. *J Pers Med* 11: 86, 2021.

23. Gong M, Li Q, Xu Y and Fu Y: The evaluation of clinical status of endoscopic retrograde cholangiography for the placement of metal and plastic stents in cholangiocarcinoma therapy. *Comput Math Methods Med* 2022: 5741437, 2022.
24. Serghiou S and Rough K: Deep learning for epidemiologists: An introduction to neural networks. *Am J Epidemiol* 192: 1904-1916, 2023.
25. Jiang H, Guo J, Li J, Li C, Du W, Canavese F, Baker C, Ying H and Hua J: Artificial neural network modeling to predict neonatal metabolic bone disease in the prenatal and postnatal periods. *JAMA Netw Open* 6: e2251849, 2023.
26. Liu X, Wang X, Yu L, Hou Y, Jiang Y, Wang X, Han J and Yang Z: A novel prognostic score based on artificial intelligence in hepatocellular carcinoma: A long-term follow-up analysis. *Front Oncol* 12: 817853, 2022.
27. Tu JV: Advantages and disadvantages of using artificial neural networks versus logistic regression for predicting medical outcomes. *J Clin Epidemiol* 49: 1225-1231, 1996.
28. Cao B, Zhang KC, Wei B and Chen L: Status quo and future prospects of artificial neural network from the perspective of gastroenterologists. *World J Gastroenterol* 27: 2681-2709, 2021.
29. Pergialiotis V, Pouliakis A, Parthenis C, Damaskou V, Chrelias C, Papantoniou N and Panayiotides I: The utility of artificial neural networks and classification and regression trees for the prediction of endometrial cancer in postmenopausal women. *Public Health* 164: 1-6, 2018.
30. Canakis A and Sharaiha RZ: Radiofrequency ablation for pancreaticobiliary disease: An updated review. *Ann Gastroenterol* 36: 497-503, 2023.
31. Nabi Z and Reddy DN: Endoscopic palliation for biliary and pancreatic malignancies: Recent advances. *Clin Endosc* 52: 226-234, 2019.
32. Grein JD and Murthy RK: New developments in the prevention of gastrointestinal scope-related infections. *Infect Dis Clin North Am* 32: 899-913, 2018.
33. Labib PL, Goodchild G and Pereira SP: Molecular pathogenesis of cholangiocarcinoma. *BMC Cancer* 19: 185, 2019.
34. Özcan Ö and Arıkan S: Determining the risk factors of complications due to endoscopic retrograde cholangiopancreatography. *Cureus* 16: e51666, 2024.
35. Agrawal S, Gupta A, Gupta S, Goyal B, Siddeek RAT, Rajput D, Chauhan U, Kishore S, Gupta M and Kant R: Role of carbohydrate antigen 19-9, carcinoembryonic antigen, and carbohydrate antigen 125 as the predictors of resectability and survival in the patients of carcinoma gall bladder. *J Carcinog* 19: 4, 2020.
36. Bekki Y, Von Ahrens D, Takahashi H, Schwartz M and Gunasekaran G: Recurrent intrahepatic cholangiocarcinoma-review. *Front Oncol* 11: 776863, 2021.
37. Yang H, Li W, Ren L, Yang Y, Zhang Y, Ge B, Li S, Zheng X, Liu J, Zhang S, *et al*: Progress on diagnostic and prognostic markers of pancreatic cancer. *Oncol Res* 31: 83-99, 2023.
38. Kubo S, Shinkawa H, Asaoka Y, Ioka T, Igaki H, Izumi N, Itoi T, Unno M, Ohtsuka M, Okusaka T, *et al*: liver cancer study group of japan clinical practice guidelines for intrahepatic cholangiocarcinoma. *Liver Cancer* 11: 290-314, 2022.
39. Zhu J, Wang D, Liu C, Huang R, Gao F, Feng X, Lan T, Li H and Wu H: Development and validation of a new prognostic immune-inflammatory-nutritional score for predicting outcomes after curative resection for intrahepatic cholangiocarcinoma: A multicenter study. *Front Immunol* 14: 1165510, 2023.
40. Bai Z, Yin Y, Xu W, Cheng G and Qi X: Predictive model of in-hospital mortality in liver cirrhosis patients with hyponatremia: An artificial neural network approach. *Sci Rep* 14: 28719, 2024.
41. Li Y, Xu T, Wang X, Jia X, Ren M and Wang X: The prognostic utility of preoperative neutrophil-to-lymphocyte ratio (NLR) in patients with colorectal liver metastasis: A systematic review and meta-analysis. *Cancer Cell Int* 23: 39, 2023.
42. Saputra HM, Hidayatullah F, Klopung YP, Renaldo J, Chung E and Hakim L: Prognostic value of neutrophil-to-lymphocyte ratio (NLR) in penile cancer: A systematic review and meta-analysis. *Ann Med Surg (Lond)* 81: 104335, 2022.
43. Buonacera A, Stancanelli B, Colaci M and Malatino L: Neutrophil to lymphocyte ratio: An emerging marker of the relationships between the immune system and diseases. *Int J Mol Sci* 23: 3636, 2022.
44. Wu L, Saxena S and Singh RK: Neutrophils in the tumor micro-environment. *Adv Exp Med Biol* 1224: 1-20, 2020.
45. Mouchli M, Reddy S, Gerrard M, Boardman L and Rubio M: Usefulness of neutrophil-to-lymphocyte ratio (NLR) as a prognostic predictor after treatment of hepatocellular carcinoma. Review article. *Ann Hepatol* 22: 100249, 2021.
46. Ney A, Garcia-Sampedro A, Goodchild G, Acedo P, Fusai G and Pereira SP: Biliary strictures and cholangiocarcinoma-untangling a diagnostic conundrum. *Front Oncol* 11: 699401, 2021.
47. Tarighati E, Keivan H and Mahani H: A review of prognostic and predictive biomarkers in breast cancer. *Clin Exp Med* 23: 1-16, 2023.
48. Zu QQ, Zhang JX, Wang B, Ye W, Liu S and Shi HB: Percutaneous transpapillary biliary stent placement for distal malignant biliary obstruction: Outcomes and survival analysis. *Turk J Gastroenterol* 30: 714-721, 2019.
49. Singh I, Chou JF, Capanu M, Park J, Yu KH, Varghese AM, Park W, Zervoudakis A, Keane F, Rolston VS, *et al*: Morbidity and mortality in patients with stage IV pancreatic adenocarcinoma and acute cholangitis: Outcomes and risk prognostication. *Pancreatology* 24: 608-615, 2024.



Copyright © 2025 Ma et al. This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.